文献速递冠心病血脂与心血管预防

癌症患者冠状动脉血运重建的结局

Coronary revascularisation outcomes in patients with cancer.
PubMed 文献 · Heart · 2021-06-15

癌症与冠心病在传统危险因素及分子机制上存在重叠,癌症患者冠心病风险增加,接受血运重建的高危人群日益增多。超过十分之一的需经皮冠状动脉介入或冠状动脉旁路移植的冠心病患者有癌症病史或活动性癌症,其血运重建结局因癌症特征而异,管理面临挑战且存在诸多证据空白。

要点

  • 超过十分之一需血运重建的冠心病患者有癌症病史或活动性癌症。
  • 癌症患者血运重建结局因癌症类型、分期、转移及治疗而异。
  • 血液学异常导致血栓与出血竞争风险,增加管理难度。

核心结论

  • 癌症合并冠心病需血运重建的患者发病和死亡风险高于无癌症患者。
  • 血运重建结局取决于癌症特征如发病时间、亚型、部位、分期、转移及治疗。

研究设计与样本

  • 综述,总结近期关于癌症患者血运重建结局、操作考虑和最佳实践的研究。

主要发现

  • 超过十分之一需经皮冠状动脉介入或冠状动脉旁路移植的冠心病患者有癌症病史或活动性癌症。
  • 癌症患者通常更年长、合并症更多、冠心病更广泛。
  • 血液学异常带来血栓和出血的竞争风险。
  • 结局因癌症类型和分期等因素而异。

临床怎么用

  • 管理需综合考虑癌症特征及血栓出血风险,但最佳实践尚待进一步研究。

局限性

  • 许多证据空白仍需进一步研究以指导临床最佳实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer and coronary artery disease (CAD) overlap in traditional risk factors as well as molecular mechanisms underpinning the development of these two disease states. Patients with cancer are at increased risk of developing CAD, representing a high-risk population that are increasingly undergoing coronary revascularisation. Over 1 in 10 patients with CAD that require revascularisation with either percutaneous coronary intervention or coronary artery bypass grafting have either a history of cancer or active cancer. These patients are typically older, have more comorbidities and have more extensive CAD compared with patients without cancer. Haematological abnormalities with competing risks of thrombosis and bleeding pose further unique challenges during and after revascularisation. Management of patients with concurrent cancer and CAD requiring revascularisation is challenging as these patients carry a higher risk of morbidity and mortality compared with those without cancer, often driven by the underlying cancer and associated comorbidities. However, due to variability by different types and stages of cancer, revascularisation outcomes are specific to cancer characteristics such as the timing of onset, cancer subtype and site, stage, presence of metastases, and cancer-related therapies received. Recent studies have provided insights into defining revascularisation outcomes, procedural considerations and best practices in managing patients with cancer. Nevertheless, many gaps remain that require further studies to inform clinical best practices in this population.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Leedy D, Tiwana JK, Mamas M, et al. Coronary revascularisation outcomes in patients with cancer. Heart. 2021. PMID: 34415850. doi:10.1136/heartjnl-2020-318531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。